EARLY CANCER CONFIRMATION TEST
Confirm cancer at its earliest stages with the IvyGene Blood Test.
In the U.S. in 2016, 4,600 individuals were diagnosed with cancer every single day. The first step to fighting cancer is identifying its presence early, which can be a difficult and frustrating process.
The IvyGene test is a blood test that can detect breast, liver, lung, and colorectal cancer earlier than any other diagnostic tool on the market. Because IvyGene uses DNA data, it can detect cancerous cells before a growth is noticed on an ultrasound.
Current cancer screening options rarely detect growths before they reach 2cm, and by then, cancer has already grown to Stage 2 - much harder to treat and eliminate. IvyGene is the non-invasive, proactive solution to catching cancer before it becomes a problem.
About The IvyGene
Who Should Use IvyGene?
Patients who are immuno-compromised, have a history of viral infections, or a family background of cancer should use the IvyGene test as their cancer screening method of choice.
Earlier detection, non-invasive, and quick results mean IvyGene is ideal for catching cancer early - which means longer life and better health.
79% Survival Rate When Caught Before Stage 2
The Science of IvyGene
DNA within cells may be modified by the addition of a methyl group (-CH3) to certain sites within the genome. In particular, the DNA base cytosine can be methylated at the C-5 position of the cytosine ring (5-methylcytosine, 5-mC). This type of DNA modification is not a mutation that alters the coding potential of the genome. Instead, this type of DNA modification acts as a heritable but reversible marker of gene expression, called an epigenetic marker.
During malignant transformation (the process by which normal cells transform into cancer cells), there are significant changes in gene expression. These changes in gene expression are highly correlated to changes to the methylation pattern of genomic DNA. Therefore, normal cells and cancer cells can be differentiated by detecting which sites within the genome are methylated.
The genomic DNA of cancer cells is shed into circulation due to cancer cell death (apoptosis or necrosis) or release from viable cells. Once the genomic DNA of a cancer cell is shed into the blood stream, it is called cell-free DNA (cfDNA). This cfDNA retains the DNA methylation pattern of the cancer cell from which is was shed.
Publications & Articles
-
2019 – White Paper Regarding the Performance Characteristics of the IvyGene test
-
2017 – Hao – DNA Methylation Markers for Diagnosis and Prognosis of common cancers
-
2017 – Guo – Tissue of origin mapping using NGS and CpG methylation of DNA in plasma
-
2017 – Galanopoulos – Review – Abnormal ctDNA Methylation for Colon Cancer Detection
-
2017 – Cheuk – Review – Methylation of ctDNA for Breast Cancer Detection
-
2015 – Warton – Review – Methylation of ctDNA for Cancer Detection
-
2012 – Diep – Library-free Methylation Sequencing with Bisulfite Padlock Probes
In the News
Laboratory For Advanced Medicine To Present At 2018 BIO International Convention
IRVINE, Calif., June 4, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced that Justin Li, General Manager and Vice President of Finance, will present at the 2018 BIO International Convention.
Laboratory For Advanced Medicine Commercializes Non-Invasive, Artificial Intelligence-Based IvyGene Blood Test For Cancer Detection
IRVINE, Calif., May 30, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced the commercialization of its revolutionary, non-invasive and highly accurate IvyGene test.